

Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2011

Fluoride-Cleavable, Fluorescently Rabelled Reversible Terminators: Synthesis and Use in Primer Extension

Diana C. Knapp,^[a] Saulius Serva,^[b] Jennifer D'Onofrio,^[a] Angelika Keller,^[a] Arvydas Lubys,^[b] Ants Kurg,^[c, d] Maido Remm,^[d] and Joachim W. Engels^{*[a]}

chem_201001952_sm_miscellaneous_information.pdf

Supporting information

<u>1</u>	EXPERIMENTAL DATA – CHEMICAL PART	4
1.1	Materials and methods	4
1.2	Introduction of the protecting groups	6
1.2.1	Synthesis of 6- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)-7-deaza-7- iodo-2'-deoxyadenosine 14	6
1.2.2	Synthesis of 6- <i>N</i> -(<i>N,N-</i> dimethylaminomethylidenyl)-7-deaza-7- iodo-5'- <i>O</i> -bezoyl-2'-deoxyadenosine 15	7
1.2.3	Synthesis of 4- <i>N-(N,N-</i> dimethylaminomethylidenyl)-5-iodo-5'- <i>O</i> - benzoyl-2'-deoxycytidine 12	8
1.2.4	Synthesis of 2- <i>N</i> -(<i>N,N</i> -dimethylaminomethylidenyl)-7-deaza-7- iodo-3',5'- <i>O</i> -(tetraisopropyldisiloxane-1,3-diyl)-2'-deoxyguanosine 17	9
1.2.5	Synthesis of 2- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)- <i>N</i> ¹ -benzoyl-7- deaza-7-iodo-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-2'- deoxyguanosine 32	10
1.2.6	Synthesis of 2- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)- <i>N</i> ¹ -benzoyl-7-deaza-7-iodo-2'-deoxyguanosine 18	11
1.2.7	Synthesis of 2- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)- <i>N</i> ¹ -benzoyl-7- deaza-7-iodo-5'- <i>O</i> -(4-monomethoxytrityl)-2'-deoxyguanosine 19	12
1.3	Introduction of the 3'- <i>O</i> -(2-cyanoethyl) group and deprotection	13
1.3.1	General procedure for the introduction of the 2-cyanoethyl group at the 3'-OH position (GP 1)	13
1.3.2	Synthesis of 6- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)-7-deaza-7- iodo-3'-(2-cyanoethyl)-5'-O-bezoyl-2'-deoxyadenosine 33	13
1.3.3	Synthesis of 7-deaza-7-iodo-3'-(2-cyanoethyl)-2'-deoxyadenosine 16	14
1.3.4	Synthesis of 4- <i>N-(N,N-</i> dimethylaminomethylidenyl)-5-iodo-5'- <i>O</i> - benzoyl-3'- <i>O</i> -(2-cyanoethyl)-2'-deoxycytidine 34	15
1.3.5	Synthesis of 5-Iodo-3'-O-(2-cyanoethyl)-2'-deoxycytidine 13	16
1.3.6	Synthesis of 2- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)- <i>N</i> ¹ -benzoyl-7- deaza-7-iodo-3'- <i>O</i> -(2-cyanoethyl)-5'- <i>O</i> -(4-monomethoxytrityl)-2'-	10
1.3.7	deoxyguanosine 20 Synthesis of 2- <i>N</i> -(<i>N</i> , <i>N</i> -dimethylaminomethylidenyl)- <i>N</i> ³ -benzoyl-7- deaza-7-iodo-3'- <i>O</i> -(2-cyanoethyl)-2'-deoxyguanosine 35	16
1.3.8	Synthesis of 7-Deaza-7-iodo-3'- <i>O</i> -(2-cyanoethyl)-2'- deoxyguanosine 21	18
1.4	Synthesis and attachment of the linker	19

2.3	7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxy-methyl}-2-	
2.2	5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-5(6)- carboxyfluoresceinamidoethoxy)ethoxy]ethoxymethyl}-2- cyanoethyl ester-3'- <i>O</i> -(2-cyanoethyl)-2'-deoxyuridine 5'- triphosphate 2	33
2.1	5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-amino- ethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'- <i>O</i> -(2- cyanoethyl)2'-desoxyuridine 5'-triphosphate 28	29
<u> </u>	SPECTRA AND CHROMATOGRAMS	29
2		28 20
1.5.7	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy5- amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2- cyanoethyl)-2'-desoxyguanosine 5'-triphosphoto 5	20
1.5.6	Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy3- amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2- cyanoethyl)2'-deoxycytidine 5'-triphosphate 4	27
1.5.5	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-5(6)- carboxyTexasRed-amidoethoxy)ethoxy]ethoxymethyl}-2- cyanoethyl ester-3'-0-(2-cyanoethyl)-2'-desoxyadenosine 5'- triphosphate 3	26
1.5.4	General procedure for the purification of labelled triphosphates (GP 4)	26
1.5.3	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'-deoxyguanosine 5'-triphosphate 31	25
1.5.2	Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'-deoxycytidine 5'-triphosphate 29	24
1.5.1	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'-deoxyadenosine 5'-triphosphate 30	23
1.5	Triphosphate synthesis and attachment of the dye	23
1.4.4	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'-desoxyguanosine 27	22
1.4.3	Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'-deoxycytidine 25	21
1.4.2	Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-O-(2-cyanoethyl)-2'desoxyadenosine 26	20
1.4.1	Synthesis of the alkyne modified linker Prop-2-inylcarbamic acid 1- {2-[2-(2- <i>tert</i> -butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2- cyanoethyl ester 23	19

	cyanoethyl ester-3'- <i>O</i> -(2-cyanoethyl)-2'-desoxyadenosine 5'- triphosphate 30	37
2.4	7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-5(6)- carboxyTexasRed-amidoethoxy)ethoxy]-ethoxymethyl}-2- cyanoethyl ester-3'- <i>O</i> -(2-cyanoethyl)-2'-desoxyadenosine 5'- triphosphate 3	41
2.5	5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]-ethoxymethyl}-2- cyanoethyl ester-3'- <i>O</i> -(2-cyanoethyl)-2'-deoxycytidine 5'- triphosphate 29	45
2.6	5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy3- amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'- <i>O</i> - (2-cyanoethyl)2'-deoxycytidine 5'-triphosphate 4	49
2.7	7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2- <i>tert</i> - butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2- cyanoethyl ester-3'- <i>O</i> -(2-cyanoethyl)-2'-desoxyguanosine 5'- triphosphate 31	53
2.8	7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy5- amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'- <i>O</i> - (2-cyanoethyl)-2'-desoxyguanosine 5'-triphosphate 5	57

1 Experimental data – chemical part

1.1 Materials and methods

The following devices and methods were used for chemical analysis:

Nuclear Magnetic Resonance spectroscopy: ¹H-NMR spectra were recorded on Bruker AM, DPX and AV instruments at 250, 300 or 400 MHz and 300 K. ¹³C spectra were recorded on Bruker AM, DPX and AV instruments at 62.5, 75, 100 or 150 MHz. Chemical shifts (δ) in ¹H-NMR and ¹³C-NMR spectra are reported in ppm relative to the solvent signal. The fine structure of proton signals was specified by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), br (broad) and in quotations for pseudo fine structures. Assignments in the ¹H-NMR and ¹³C-NMR spectra were made by DEPT, COSY, HSQC and HMBC experiments.

Thin Layer chromatography (TLC): Recorded on Polygram[®] Sil G/UV₂₅₄ by Macherey Nagel & Co., Dueren (thickness of layer 0.2 mm), 60 F_{254} from Merck KGaA, Darmstadt (thickness of layer 0.2 mm) or RP-18W with fluorescence indicator 254 nm from Sigma-Aldrich Chemie GmbH, Steinheim (thickness of layer 0.15 mm).

Column-chromatography was carried out on silica gel 60 (40-63 μ m) by Merck KGaA, Darmstadt at normal pressure or on silica gel 60 (15-40 μ m) by Merck KGaA, Darmstadt at a pressure of 2-3 bar (**flash-chromatography**).

Fast Protein Liquid Chomatography[®] (FPLC[®]) was performed at 4 °C on a Pharmacia FPLC[®] system equipped with a Single Path Monitor UV-1 UV detector (254 nm) and self-packed columns of different sizes with DEAE Sepharose[®] material from Sigma-Aldrich for ion-exchange FPLC[®] (0.05 M triethylammonium hydrogencarbonate (TEAB)-buffer pH = 8.0 (A)/0.8 M TEAB-buffer pH = 8.0 (B) as eluent) or Octadecyl-functionalised silica gel from Sigma-Aldrich (water (A)/CH₃CN (B) as eluent) for reversed-phase FPLC[®].

Reversed-phase (RP) HPLC was performed on a Jasco LC-2000Plus HPLC system equipped with a Jasco UV 2075Plus detector (detection at 254 nm) and a Shimadzu RF-353 fluorescence detector (excitation and emission at the specific wavelength of the dye used). For reversed-phase separation Phenomenex Jupiter 4 μ Proteo 90A 4 μ m columns (250x15 mm for preparative and 250x4.6 mm for analytical separations) were used with 1 M triethylammonium acetate (TEAA)-buffer pH = 6.5 (A)/water (B)/CH₃CN (C) as eluents. UV detection was accomplished at 254 nm.

Ion-exchange HPLC was performed on a Jasco LC-900 HPLC system equipped with a Jasco UV-970 detector (detection at 254 nm) and a Dionex BioLC[®] DNAPac[®] PA-100 (250x9 mm) using water/0.25 M tris(hydroxymethyl)-aminomethane hydrochloride (Tris-Cl) buffer pH = 8/1 M sodium chloride solution as eluents. **Mass spectrometry** (MS): ESI-MS was performed on a Fisons instrument equipped with a VG platform II with quadrupol analyser.

UV spectroscopy was performed on a Jasco V-650 spectrometer using 0.1 cm cuvettes.

Fluorescence spectroscopy was performed on a Hitachi F4500 fluorescence spectrometer using 0.3 cm cuvettes.

Elemental analyses (EA) were recorded on a Foss-Heraeus CHN-O Rapid instrument.

The **numbering of the atoms** to assign the NMR signals, are not related to the IUPAC numbering or the numbers used in the names of the compounds.

Abbreviations used: arrayed primer extension (APEX), benzoyl (chloride) (Bz(Cl)), *tert*butoxycarbonyl (Boc), bovine serum albumin (BSA), calculated (calc.); 2-cyanoethyl (CE), 2'deoxynucleoside-5'-triphosphate (dNTP), 2'-deoxyguanosine-5'-triphosphate (dATP), 2'deoxycytidine-5'-triphosphate (dCTP), 2'-deoxyguanosine-5'-triphosphate (dGTP), 2'deoxythymidine-5'-triphosphate (dTTP), 2',3'-didesoxyadenosine-5'-triphosphate (dATP), diethylaminoethyl (DEAE), *N*,*N*'-hydroxysuccinimidyl carbonate (DSC), *N*,*N*dimethylaminopyridine (DMAP), *N*,*N*-dimethylformamide (DMF), dimethylsulfoxide (DMSO), dithiothreitol (DTT), elemental analysis (EA), electrospray ionisation mass spectroscopy (ESI-MS), ethylenediaminetetraacetate (EDTA), fast protein liquid chromatography (FPLC), high-performance liquid chromatography (HPLC), ion-exchange (IE), 4-monomethoxytrityl (chloride (MMTr(Cl)), nuclear magnetic resonance (NMR), polyacylamide (PAA), reversed-phase (RP), single nucleotide polymorphism (SNP), terminal deoxynucleotidyl transferase (TdT), tetrabutylammonium fluoride (TBAF), *p*-toluenesulfonic acid (PTSA), triethylammonium acetate (TEAA), triethylammonium hydrogencarbonate (TEAB), trifluoroacetic acid (TFA), tetrahydrofuran (THF), thin layer chromatography (TLC).

5-Iodo-2'-deoxyuridine **6** was purchased from Pharma-Waldhof GmbH, Düsseldorf, Germany. 7-Iodo-7-deaza-2'-deoxyguanosine **9** was purchased from ChemBiotech GmbH, Münster, Germany.

1.2 Introduction of the protecting groups

1.2.1 Synthesis of 6-*N*-(*N*,*N*-dimethylaminomethylidenyl)-7-deaza-7iodo-2'-deoxyadenosine 14



7-Deaza-7-iodo-2'-deoxyadenosine **8** (2.5 g, 6.6 mmol, 1.0 eq.) was dissolved in 40 mL of DMF and treated with 15 mL (9.9 mmol, 1.5 eq.) of *N*,*N*-dimethylformamide dimethyl acetal and the reaction was stirred at 50 °C for 2 h. Thereafter the reaction was concentrated under reduced pressure and purified by silica gel chromatography (CH₂Cl₂/MeOH = 95:5 to CH₂Cl₂/MeOH = 90:10) affording 2.9 g (95 %) of compound **14** as yellow solid.

TLC: **R**_F = 0.27 (CH₂Cl₂/MeOH = 90:10); ¹H-NMR (100 MHz, DMSO-d₆, 300 K): δ = 2.16 (m, 2'-H), 2'-H' signal is hidden under DMSO residual signal, 3.18 (s, 11-H₃), 3.23 (s, 11-H₃'), 3.55 (m, 5'-H₂), 3.82 (br. s, 4'-H), 4.34 (br. s, 3'-H), 5.03 (br. t, 5'-OH), 5.26 (d, 3'-OH), 6.53 (t, 1'-H), 7.71 (s, 8-H), 8.32 (s, 2-H), 8.83 (s, 10-H) ppm; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): δ = 34.77 (11-C), 39.72 (2'-C), 40.27 (11-C'), 53.48 (7-C), 61.80 (5'-C), 70.88 (3'-C), 82.80 (1'-C), 87.31 (4'-C), 110.08 (5-C), 128.39 (8-C), 150.67 (4-C), 151.27 (2-C), 156.02 (10-C), 159.98 (6-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 431.04 [C₁₄H₁₈IN₅O₃], found: 431.8 [M+H]⁺.

1.2.2 Synthesis of 6-*N*-(*N*,*N*-dimethylaminomethylidenyl)-7-deaza-7iodo-5'-*O*-bezoyl-2'-deoxyadenosine 15



Compound **14** (2.9 g, 6.2 mmol, 1.0 eq.) was dissolved in 150 mL of dry pyridine and cooled to -15 °C. Benzoyl chloride (700 μ L, 6.6 mmol, 1.06 eq.) was dissolved in 40 mL of dry CH₂Cl₂, added to the reaction mixture and the mixture was stirred at -15 °C for 1 h. The reaction was quenched with MeOH, concentrated under reduced pressure and purified by silica gel chromatography (CH₂Cl₂/MeOH = 98:2 to CH₂Cl₂/MeOH = 90:10) affording 3.0 g (5.6 mmol, 89 %) of compound **15** as slightly yellow solid.

TLC: **R**_F = 0.45 (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (400 MHz, DMSO-d₆, 300 K): δ = 2.30 (ddd, 2'-H), 2.66 (m, 2'-H'), 3.18 (s, 11-H₃), 3.22 (s, 11-H₃'), 4.11 (q, 4'-H), 4.41 (dd, 5'-H), 4.52 (m, 3'-H, 5'-H'), 5.52 (d, 3'-OH), 6.58 (t, 1'-H), 7.55 (t, 15-H₂), 7.64 (s, 8-H), 7.67 (t, 16-H), 7.98 (d, 14-H₂), 8.32 (s, 2-H), 8.83 (s, 10-H) ppm, $J_{15,16}$ = 7.38 Hz; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): δ = 34.76 (11-C), 38.67 (2'-C), 40.27 (11-C), 54.01 (7-C), 64.43 (5'-C), 70.45 (3'-C), 82.44 (1'-C), 83.51 (4'-C), 110.07 (5-C), 128.11 (8-C), 128.76 (15-C), 129.09 (14-C), 129.32 (13-C), 133.34 (16-C), 150.81 (4-C), 151.45 (2-C), 152.02 (10-C), 160.01 (6-C), 165.48 (12-C) ppm; **ESI**(+)-**MS** (*m/z*): calc.: 535.07 [C₂₁H₂₂IN₅O₄], found: 535.9 [M+H]⁺; **EA** (%): calc.: C: 47.12, H: 4.14, N: 13.08, found: C: 46.95, H: 4.29, N: 12.85.

1.2.3 Synthesis of 4-*N*-(*N*,*N*-dimethylaminomethylidenyl)-5-iodo-5'-*O*benzoyl-2'-deoxycytidine 12



Well dried N^4 -(*N*,*N*-dimethylaminomethylidenyl)-5-iodo-2'-deoxy-cytidine **11** (1.0 g, 2.45 mmol, 1.0 eq.) was dissolved in 45 mL of dry pyridine and 10 mL of dry DMF. The pale-yellow solution was cooled to 0 °C and 385 µL (3.28 mmol, 1.3 eq.) of benzoyl chloride in 4 mL of dry pyridine were added drop wise via a syringe within 2 h. After stirring the mixture under an Ar atmosphere for further 30 min at room temperature, the solvents were evaporated and the yellow oily residue was purified by column chromatography (CH₂Cl₂/MeOH = 95:5 to CH₂Cl₂/MeOH = 90:10) yielding 750 mg (1.46 mmol, 60 %) of compound **12** as colourless solid.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.22 \text{ (CH}_2\text{Cl}_2/\text{MeOH} = 90:10); ^1\text{H-NMR} (400 \text{ MHz, DMSO-d}_6, 300 \text{ K}): <math>\delta = 2.12-2.33$ (m, 2'-H₂), 3.12 (s, 8-H₃), 3.21 (s, 8-H₃'), 4.16 (m, 4'-H), 4.35 (m, 3'-H), 4.51 (m, 5'-H₂), 5.45 (d, 3'-OH), 6.14 (,,t", 1'-H), 7.55 (t, 12-H₂), 7.68 (t, 13-H), 8.01 (d, 11-H₂), 8.07 (s, 6-H), 8.56 (s, 7-H), ppm; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): $\delta = 34.92$ (8-C), 40.16 (2'-C), 40.93 (8-C'), 64.50 (5'-C), 69.17 (5-C), 70.51 (3'-C), 84.40 (4'-C), 86.13 (1'-C), 128.96 (12-C), 129.28 (11-C), 130.51 (10-C), 133.52 (13-C), 146.59 (6-C), 154.05 (2-C), 158.32 (7-C), 165.64 (9-C), 168.11 (4-C) ppm; **ESI**(+)-MS (*m*/*z*): calc.: 512.30 [C₁₉H₂₁IN₄O₅], found: 513.0 [M+H]⁺.

1.2.4 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-7-deaza-7iodo-3',5'-*O*-(tetraisopropyldisiloxane-1,3-diyl)-2'deoxyguanosine 17



7-Deaza-7-iodo-2'-deoxyguanosine **9** (1.0 g, 2.55 mmol, 1.0 eq.) was co-evaporated three times with dry pyridine, then dissolved in 10 mL of dry pyridine and cooled down to 0 °C. 1,1,3,3-Tetraisopropyldichlordisiloxane (0.88 mL, 2.81 mmol, 1.1 eq.) was added and the mixture was stirred under an Ar atmosphere for 30 min at 0 °C and for 20 h at room temperature. The reaction was stopped by addition of 10 mL of MeOH and the resulting mixture stirred for 15 min. The solvents were removed in vacuum, the oily residue was dissolved in 15 mL of dry DMF again and treated with 1.7 mL (12.8 mmol, 5.0 eq.) of *N*,*N*-dimethylformamide dimethylacetal. The clear solution was stirred 24 h at room temperature under an Ar atmosphere. After completion of the reaction, the mixture was concentrated and the crude product purified by column chromatography (CH₂Cl₂/MeOH = 95:5 to CH₂Cl₂/MeOH = 90:10) yielding 1.73 g (95 %) of compound **17** as yellowish foam.

TLC: **R**_F = 0.20 (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): δ = 0.99-1.15 (m, 13-H, 14-H, 15-H, 16-H, 17-H₃, 18-H₃, 19-H₃, 20-H₃, 21-H₃, 22-H₃, 23-H₃, 24-H₃), 2.42 (m, 2'-H₂), 3.02, 3.14 (s, 11-H₃, 12-H₃), 3.71 (m, 4'-H), 3.89 (d, 5'-H₂), 4.67 (q, 3'-H), 6.36 (dd, 1'-H), 7.12 (s, 8-H), 8.57 (s, 10-H), 11.09 (s, N¹*H*) ppm; ¹³**C-NMR** (75 MHz, DMSO-d₆, 300 K): δ = 11.86, 12.05, 12.40, 12.62 (13-C, 14-C, 15-C, 16-C), 16.66, 16.73, 16.76, 16.90, 17.04, 17.15, 17.17, 17.19 (17-C, 18-C, 19-C, 20-C, 21-C, 22-C, 23-C, 24-C), 34.45, 40.41 (11-C, 12-C), 40.26 (2'-C), 55.35 (7-C), 61.85 (5'-C), 70.55 (3'-C), 80.30 (1'-C), 83.89 (4'-C), 102.60 (5-C), 122.46 (8-C), 149.02 (4-C), 156.15 (2-C), 157.54 (10-C), 158.72 (6-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 689.19 [C₂₆H₄₄IN₅O₅Si₂], found.: 690.1 [M+H]⁺; **EA** (%): calc.: C: 45.28, H: 6.43, N: 10.15, found: C: 45.45, H: 6.47, N: 10.12.

1.2.5 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-*N*¹-benzoyl-7-deaza-7-iodo-3',5'-*O*-(tetraisopropyldisiloxane-1,3-diyl)-2'deoxyguanosine 32



Compound **17** (1.5 g, 2.17 mmol, 1.0 eq.) was dissolved in 15 mL of dry pyridine and the reaction was cooled to 0 °C. Benzoyl chloride (514 μ L, 4.42 mmol, 2.0 eq.) was dissolved in 500 μ L of dry CH₂Cl₂ and added drop wise. The reaction was warmed to room temperature and stirred for 2 h. After 2 h another 100 μ L (0.86 mmol, 0.4 eq.) of benzoyl chloride were added and the reaction mixture stirred at room temperature for 18 h. The reaction was quenched by addition of MeOH, concentrated under reduced pressure and purified by flash-column chromatography (CH₂Cl₂/MeOH = 99:1 to CH₂Cl₂/MeOH = 98:2) affording 1.2 g (69 %) of compound **32** as colourless foam.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.61$ (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): $\delta = 1.13-1.01$ (m, 13-H, 14-H, 15-H, 16-H, 17-H₃, 18-H₃, 19-H₃, 20-H₃, 21-H₃, 22-H₃, 23-H₃, 24-H₃), 2'-H₂ signals are hidden below the DMSO residual peak, 2.62, 3.08 (s, 11-H₃, 12-H₃) 3.76 (m, 4'-H), 3.96 (d, 5'-H₂), 4.71 (q, 3'-H), 6.44 (dd, 1'-H), 7.25 (s, 8-H), 7.54 (t, 28-H₂), 7.69 (t, 29-H), 7.78 (d, 27-H₂), 8.60 (s, 10-H) ppm.; ¹³**C-NMR** (75 MHz, DMSO-d₆, 300 K): $\delta = 11.87$, 12.06, 12.41, 12.64, (13-C, 14-C, 15-C, 16-C), 16.66, 16.73, 16.78, 16.92, 17.04, 17.16, 17.19, 17.21 (17-C, 18-C, 19-C, 20-C, 21-C, 22-C, 23-C, 24-C), 34.23, 40.47 (11-C, 12-C), 39.22 (2'-C), 55.79 (7-C), 61.78 (5'-C), 70.44 (3'-C), 80.50 (1'-C), 84.82 (4'-C), 102.01 (5-C), 123.37 (8-C), 128.99 (28-C), 129.39 (27-C), 132.93 (26-C), 134.09 (29-C), 148.33 (4-C), 153.82 (2-C), 156.57 (10-C), 157.68 (6-C), 171.30 (25-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 793.22 [C₃₃H₄₈IN₅O₆Si₂], found: 794.5 [M+H]⁺.

1.2.6 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-*N*¹-benzoyl-7-deaza-7-iodo-2'-deoxyguanosine 18



Compound **32** (1.0 g, 1.26 mmol, 1.0 eq.) was dissolved in 15 mL of THF and 720 μ L of Et₃N 3HF (approx. 37 % HF) were added. The reaction was stirred at room temperature for 1 h, afterwards the reaction was concentrated under reduced pressure and purified by flash-column chromatography (CH₂Cl₂/MeOH = 98:2 to CH₂Cl₂/MeOH = 95:5) affording 650 mg (97 %) of compound **18** as yellowish solid.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.10 (CH_2Cl_2/MeOH = 90:10)$; ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): $\delta = 2.17$ (ddd, 2'-H), 2.42 (m, 2'-H'), 2.61, 3.09 (s, 11-H₃, 12-H₃), 3.56 (m, 5'-H₂), 3.81 (m, 4'-H), 4.35 (m, 3'-H), 4.94 (t, 5'-O*H*), 6.29 (d, 3'-O*H*), 6.48 (dd, 1'-H), 7.40 (s, 8-H), 7.57 (t, 16-H₂), 7.71 (m, 17-H), 7.80 (m, 15-H₂), 8.58 (s, 10-H) ppm; ¹³**C-NMR** (75 MHz, DMSO-d₆, 300 K): $\delta = 34.39$, 40.60 (11-C, 12-C), 39.98 (2'-C), 55.60 (7-C), 61.84 (5'-C), 70.94 (3'-C), 82.48 (1'-C), 87.43 (4'-C), 102.15 (5-C), 124.18 (8-C), 129.23 (16-C), 129.54 (15-C), 133.08 (14-C), 134.25 (17-C), 148.69 (4-C), 153.78 (2-C), 156.50 (10-C), 157.84 (6-C), 171.53 (13-C) ppm; **ESI**(+)-**MS** (*m/z*): calc.: 551.07 [C₂₁H₂₂IN₅O₅] found: 552.0 [M+H]⁺.

1.2.7 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-*N*¹-benzoyl-7-deaza-7-iodo-5'-*O*-(4-monomethoxytrityl)-2'-deoxyguanosine 19



Compound **18** (600 mg, 1.17 mmol, 1.0 eq.) was dissolved in 10 mL of dry pyridine, 13 mg (0.12 mmol, 0.1 eq.) of *N*,*N*-dimethylaminopyridine (DMAP) and 500 mg (1.52 mmol, 1.3 eq.) of MMTrCl were added and the reaction stirred at room temperature for 18 h. After 18 h the reaction was quenched with MeOH, concentrated under reduced pressure and purified by flash-column chromatography (CH₂Cl₂/Et₃N = 100:0.1 to CH₂Cl₂/MeOH/Et₃N = 99:1:0.1) affording 1 g (71 %) of compound **19** as yellow foam.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.25$ (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (400 MHz, DMSO-d₆, 300 K): $\delta = 2.25$ (m, 2'-H₂), 2.61, 3.08 (s, 11-H₃, 12-H₃), 3.11 (m, 5'-H), 3.25 (m, 5'-H'), 3.75 (s, 29-H₃), 3.94 (m, 4'-H), 4.36 (br. s, 3'-H), 5.35 (d, 3'-OH), 6.51 (t, 1'-H), 6.89 (br. d, 25-H₂), 7.24-7.42 (m, 8-H, 20-H₄, 21-H₄, 22-H₂, 24-H₂), 7.54 (t, 16-H₂), 7.70 (t, 17-H), 7.79 (d, 15-H₂), 8.58 (s, 10-H) ppm, $J_{16,17} = 7.31$ Hz; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): $\delta = 34.27$, 40.47 (11-C, 12-C), 39.85 (2'-C), 54.95 (29-C), 55.70 (7-C), 64.29 (5'-C), 70.64 (3'-C), 82.26 (1'-C), 85.76 (4'-C), 102.13 (5-C), 113.09 (25-C), 123.71 (8-C), 126.71, 127.73, 127.80 128.99 (20-C, 21-C, 22-C, 24-C), 129.40 (16-C), 129.84 (15-C), 132.95 (14-C), 134.09 (17-C), 134.83 (23-C), 144.01 (19-C), 144.14 (19-C'), 148.53 (4-C), 153.69 (2-C), 156.37 (10-C), 157.70 (28-C), 158.04 (6-C), 171.36 (13-C), ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 823.19 [C₄₁H₃₈IN₅O₆], found: 824.5 [M+H]⁺; **EA** (%): calc.: C: 59.79, H: 4.65, N: 8.50, found: C: 60.00, H: 4.65, N: 8.50.

1.3 Introduction of the 3'-*O*-(2-cyanoethyl) group and deprotection

1.3.1 General procedure for the introduction of the 2-cyanoethyl group at the 3'-OH position (GP 1)

Derived from the method developed for the 2'-position of RNA by Saneyoshi *et al.*^[1] the following procedure was used to introduce the 2-cyanoethyl group to the 3'-OH function of our protected DNA nucleosides **15**, **12** and **19**.

In a well dried Erlenmeyer flask, equipped with a big triangle stirring bar and a septum connected to an argon line, the fully protected nucleoside was dissolved in 20 eq. of freshly distilled acrylonitrile and stirred vigorously for 5 min. To the concentrated solution *t*BuOH (3 mL/mmol to 9 mL/mmol, depending on the solubility of the nucleoside) was added. For the 2'-deoxycytidine derivative **12** DMF was necessary as additional co-solvent (3 mL/mmol). The resulting solution again was stirred vigorously for 5 min before 1 eq. of Cs_2CO_3 was added. The heterogeneous mixture was stirred vigorously for 2 to 3 h at room temperature, then filtrated over silica gel and the solvents removed under reduced pressure. The crude product was either additionally purified by column chromatography or directly used for the subsequent deprotection.

[1] H. Saneyoshi; K. Seio; M. Sekine J. Org. Chem. 2005, 70, 10453-10460.

1.3.2 Synthesis of 6-*N*-(*N*,*N*-dimethylaminomethylidenyl)-7-deaza-7iodo-3'-(2-cyanoethyl)-5'-*O*-bezoyl-2'-deoxyadenosine 33



Following **GP 1** the reaction of 3.0 g (5.6 mmol, 1.0 eq.) of compound **15**, dissolved in 7.5 mL (113.37 mmol, 20 eq.) of acrylonitrile and 20 mL of *t*BuOH, with 1.8 g (5.6 mmol, 1.0 eq.) of Cs_2CO_3 gave after filtration over silica gel (CH₂Cl₂/MeOH = 90:10) 3.2 g (quantitative yield) of compound **33** as yellowish foam.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.50 \text{ (CH}_2\text{Cl}_2/\text{MeOH} = 95:5); ^{1}$ **H-NMR** (400 MHz, DMSO-d₆, 300 K): $\delta = 2.46 \text{ (m, 2'-H)}$, 2.76 (m, 2'-H'), 2.84 (t, 18-H₂), 3.18 (s, 11-H₃), 3.22 (s, 11-H₃'), 3.75 (t, 17-H₂), 4.29 (br. q, 4'-H), 4.42-4.55 (m, 3'-H, 5'-H₂), 6.55 (t, 1'-H), 7.55 (t, 15-H₂), 7.67 (m, 8-H, 16-H), 7.99 (d, 14-H₂), 8.31 (s, 2-H), 8.83 (s, 10-H) ppm, $J_{17,18} = 5.99 \text{ Hz}; ^{13}$ **C-NMR** (100 MHz, DMSO-d₆, 300 K): $\delta = 18.15 \text{ (18-C)}, 34.76 \text{ (11-C)}, 36.05 (2'-C), 40.25 (11-C'), 54.18 (7-C), 63.65 (17-C), 64.46 (5'-C), 79.08 (3'-C), 80.95 (4'-C), 82.54 (1'-C), 110.05 (5-C), 119.05 (19-C), 128.02 (8-C), 128.74 (15-C), 129.10 (14-C), 129.23 (13-C), 133.35 (16-C), 150.89 (4-C), 151.46 (2-C), 156.03 (10-C), 160.02 (6-C), 165.42 (12-C) ppm;$ **ESI**(+)-**MS**(*m*/*z*): calc.: 588.09 [C₂₄H₂₅IN₆O₄], found: 588.9 [M+H]⁺.

1.3.3 Synthesis of 7-deaza-7-iodo-3'-(2-cyanoethyl)-2'-deoxyadenosine 16



Compound **33** (3.2 g, 5.6 mmol, 1.0 eq.) was dissolved in 200 mL of saturated methanolic ammonia and stirred at 50 °C for 2 h. After 2 h the mixture was evaporated under reduced pressure and purified by silica gel chromatography (CH₂Cl₂/MeOH = 95:5 to CH₂Cl₂/MeOH = 80:20) affording 2.3 g (96 %) of compound **16** colourless solid.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.49$ (CH₂Cl₂/MeOH = 95:5); ¹H-NMR (400 MHz, DMSO-d₆, 300 K): $\delta = 2.33$ (ddd, 2'-H), 2.55 (m, 2'-H'), 2.81 (t, 11-H₂), 3.55 (m, 5'-H), 3.67 (t, 10-H₂), 3.97 (m, 4'-H), 4.24 (m, 3'-H), 5.15 (t, 5'-OH), 6.44 (dd, 1'-H), 6.68 (br. s, 6-NH₂), 7.68 (s, 8-H), 8.10 (s, 2-H) ppm, $J_{1',2'} = 5.80$ Hz, $J_{10,11} = 6.15$ Hz; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): $\delta = 18.15$ (11-C), 36.42 (2'-C), 51.89 (7-C), 61.70 (5'-C), 63.28 (10-C), 79.74 (3'-C), 82.79 (1'-C), 84.50 (4'-C), 103.05 (5-C), 119.06 (12-C), 126.57 (8-C), 149.68 (4-C), 151.85 (2-C), 157.04 (6-C) ppm; ESI(+)-MS (*m*/*z*): calc.: 429.03 [C₁₄H₁₆IN₅O₃], found: 430.1 [M+H]⁺; EA (%): calc.: C: 39.18, H: 3.76, N: 16.32, found: C: 39.25, H: 3.89, N: 16.07.

1.3.4 Synthesis of 4-*N-(N,N-*dimethylaminomethylidenyl)-5-iodo-5'-*O*benzoyl-3'-*O*-(2-cyanoethyl)-2'-deoxycytidine 34



Following **GP 1** 652 mg (2 mmol, 1.0 eq.) of Cs_2CO_3 were added to a solution of 1.02 g (2 mmol, 1.0 eq.) of compound **12**, dissolved in 2.6 mL (40 mmol, 20 eq.) of acrylonitrile, 12 mL of *t*BuOH and 6 mL of dry DMF. The reaction afforded after filtration over silica gel (CH₂Cl₂/MeOH = 90:10) and additional purification by column chromatography (CH₂Cl₂/MeOH = 98:2 to CH₂Cl₂/MeOH = 90:10) 1.0 g (88 %) of the target compound **34** as yellow foam.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.37 \text{ (CH}_2\text{Cl}_2/\text{MeOH} = 90:10); ^1\text{H-NMR} (400 \text{ MHz, DMSO-d}_6, 300 \text{ K}): <math>\delta = 2.59-2.77$ (m, 2'-H₂), 2.61 (t, 15-H₂), 3.16 (s, 8-H₃), 3.18 (s, 8-H₃'), 3.72 (t, 14-H₂), 4.18 (m, 4'-H), 4.42 (m, 3'-H), 4.59 (m, 5'-H₂), 6.21 (dd, 1'-H), 7.44 (,,t", 12-H₂), 7.56 (,,t", 13-H), 8.01 (m, 11-H₂), 8.06 (s, 6-H), 8.68 (s, 7-H) ppm, $J_{13,14} = 6.06 \text{ Hz}; ^{13}\text{C-NMR}$ (100 MHz, DMSO-d₆, 300 K): $\delta = 19.08 \text{ (15-C)}, 35.62 (8-C), 38.81 (2'-C), 41.59 (8-C'), 64.34 (14-C), 64.41 (5'-C), 69.46 (5-C), 80.33 (3'-C), 83.04 (4'-C), 87.20 (1'-C), 117.55 (16-C), 128.86 (12-C), 129.29 (11-C), 129.72 (10-C), 133.64 (13-C), 146.08 (6-C), 155.34 (2-C), 158.91 (7-C), 166.26 (9-C), 168.93 (4-C) ppm;$ **ESI**(+)-**MS**(*m/z*): calc.: 565.36 [C₂₂H₂₄IN₅O₅], found: 565.8 [M+H]⁺.

1.3.5 Synthesis of 5-lodo-3'-O-(2-cyanoethyl)-2'-deoxycytidine 13



The fully protected compound **34** (250 mg, 0.44 mmol, 1.0 eq.) was dissolved in 50 mL saturated methanolic ammonia and stirred at room temperature for 2.5 h. The mixture was concentrated in vacuum and the residue purified on a silica gel column ($CH_2Cl_2/MeOH = 95:5$) affording 147 mg (82 %) of compound **13** as colourless solid.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.41$ (CH₂Cl₂/MeOH = 90:10); ¹**H-NMR** (400 MHz, DMSO-d₆, 300 K): $\delta = 2.06-2.30$ (m, 2'-H₂), 2.77 (t, 8-H₂), 3.60 (m, 5'-H₂), 3.62 (t, 7-H₂), 3.94 (m, 4'-H), 4.12 (m, 3'-H), 5.18 (t, 5'-OH), 6.05 (dd, 1'-H), 6.62 (br. s, 4-NH), 7.82 (br. s, 4-NH), 8.24 (s, 6-H) ppm, $J_{7,8} = 6.06$ Hz; ¹³**C-NMR** (100 MHz, DMSO-d₆, 300 K): $\delta = 18.34$ (8-C), 37.68 (2'-C), 56.81 (5-C), 61.15 (5'-C), 63.62 (7-C), 79.19 (3'-C), 84.74 (4'-C), 85.32 (1'-C), 119.26 (9-C), 147.24 (6-C), 153.83 (2-C), 163.74 (4-C) ppm; **ESI(-)-MS** (*m*/*z*): calc.: 406.18 [C₁₂H₁₅IN₄O₄], found: 404.9 [M-H]⁻. **EA** (%): calc.: C: 35.48, H: 3.72, N: 13.79, found: C: 35.35, H: 3.93, N: 13.62.

1.3.6 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-*N*¹-benzoyl-7-deaza-7-iodo-3'-*O*-(2-cyanoethyl)-5'-*O*-(4-monomethoxytrityl)-2'-deoxyguanosine 20



Following **GP 1** the reaction of 700 mg (0.84 mmol, 1.0 eq.) of compound **19**, dissolved in 1.2 mL (17 mmol, 20 eq.) of acrylonitrile and 7.5 mL of *t*BuOH with 280 mg (0.84 mmol, 1.0 eq.) of

 Cs_2CO_3 afforded after filtrated over silica gel (CH₂Cl₂ to CH₂Cl₂/MeOH = 95:5) 650 mg (88 %) of compound **20** as yellow foam.

TLC: **R**_F = 0.27 (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): δ = 2.43 (ddd, 2'-H), 2.58 (m, 2'-H'), 2.78 (t, 31-H₂), 2.61, 3.06 (s, 11-H₃, 12-H₃), 3.18 (m, 5'-H), 3.29 (m, 5'-H'), 3.65 (m, 30-H₂), 3.75 (s, 29-H₃), 4.02 (m, 4'-H), 4.31 (m, 3'-H), 6.47 (t, 1'-H), 6.89 (d, 25-H₂), 7.23-7.40 (m, 8-H, 20-H₄, 21-H₄, 22-H₂, 24-H₂), 7.41 (t, 16-H₂), 7.67 (t, 17-H), 7.81 (d, 15-H₂), 8.58 (s, 10-H) ppm; ¹³C-NMR (75 MHz, DMSO-d₆, 300 K): δ = 18.17 (31-C), 34.25, 40.45 (11-C, 12-C), 36.69 (2'-C), 54.95 (29-C), 55.88 (7-C), 63.45 (30-C), 63.02 (5'-C), 79.26 (3'-C), 82.24 (1'-C), 82.81 (4'-C), 102.15 (5-C), 113.14 (25-C), 123.76 (8-C), 126.77, 127.79, 127.85, 129.01, (20-C, 21-C, 22-C, 24-C), 118.98 (32-C), 129.40 (16-C), 129.85 (15-C), 132.93 (14-C), 134.11 (17-C), 134.76 (23-C), 143.95 (19-C), 144.05 (19-C'), 148.63 (4-C), 153.76 (2-C), 156.45 (10-C), 157.70 (28-C), 158.09 (6-C), 171.34 (13-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 876.21 [C₄₁H₃₈IN₅O₆], found: 877.6 [M+H]⁺; **EA** (%): calc.: C: 60.28, H: 4.71, N: 9.59, found: C: 60.36, H: 4.98, N: 9.62.

1.3.7 Synthesis of 2-*N*-(*N*,*N*-dimethylaminomethylidenyl)-*N*³-benzoyl-7-deaza-7-iodo-3'-*O*-(2-cyanoethyl)-2'-deoxyguanosine 35



Compound **20** (650 mg, 0.74 mmol, 1.0 eq.) was dissolved in 5 mL of CH_2Cl_2 and 5 mL of EtOH, 300 mg (1.48 mmol, 2.0 eq.) of PTSA were added and the reaction stirred at room temperature for 1 h. Afterwards the solvents were evaporated under reduced pressure, the crude product dissolved in 100 mL of CH_2Cl_2 and washed with 50 mL of saturated NaHCO₃ and saturated NaCl solution. The combined organic layers were dried over sodium sulfate, the solvents evaporated in vacuum and the residue purified by flash-column chromatography ($CH_2Cl_2/MeOH = 99:1$ to $CH_2Cl_2/MeOH = 90:10$) affording 300 mg (67 %) of compound **35** as yellow foam.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.39$ (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): $\delta = 2.42$ (ddd, 2'-H), 2'-H' signal hidden below DMSO residual signal, 2.82 (t, 19-H₂), 2.61, 3.08 (s, 11-H₃, 12-S17)

H₃), 3.58 (m, 5'-H₂), 3.69 (t, 18-H₂), 3.97 (m, 4'-H), 4.25 (m, 3'-H), 5.06 (t, 5'-O*H*), 6.45 (dd, 1'-H), 7.44 (s, 8-H), 7.55 (t, 16-H₂), 7.70 (m, 17-H), 7.81 (m, 15-H₂), 8.58 (s, 10-H) ppm; ¹³C-NMR (75 MHz, DMSO-d₆, 300 K): δ = 18.22 (19-C), 34.26, 40.47 (11-C, 12-C), 36.90 (2'-C), 55.69 (7-C), 61.69 (5'-C), 63.28 (18-C), 79.70 (3'-C), 82.35 (1'-C), 84.60 (4'-C), 102.05 (5-C), 119.15 (20-C), 123.98 (8-C), 129.06 (16-C), 129.43 (15-C), 132.93 (14-C), 134.16 (17-C), 148.65 (4-C), 153.74 (2-C), 156.49 (10-C), 157.72 (6-C), 171.38 (13-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 604.09 [C₂₄H₂₅IN₆O₅], found: 605.2 [M+H]⁺; **EA** (%): calc.: C: 47.69, H: 4.17, N: 13.90, found: C: 47.41, H: 4.26, N: 13.70.

1.3.8 Synthesis of 7-Deaza-7-iodo-3'-*O*-(2-cyanoethyl)-2'-deoxyguanosine 21



Compound **35** (250 mg, 0.41 mmol) was dissolved in 10 mL of MeOH and 10 mL of 32 % aqueous NH₃ were added. The reaction was stirred at room temperature for 18 h. The mixture was then evaporated under reduced pressure and purified by flash-column chromatography (CH₂Cl₂/MeOH = 98:2 to CH₂Cl₂/MeOH = 90:10) affording 170 mg (93 %) of compound **21** as yellowish solid.

TLC: $\mathbf{R}_{\mathbf{F}} = 0.02 \text{ (CH}_2\text{Cl}_2/\text{MeOH} = 90:10); ^1\text{H-NMR} (300 \text{ MHz}, \text{DMSO-d}_6, 300 \text{ K}): <math>\delta = 2.24 \text{ (ddd,}$ 2'-H), 2.42 (m, 2'-H'), 2.79 (t, 11-H₂), 3.50 (t, 5'-H₂), 3.65 (t, 10-H₂), 3.90 (m, 4'-H), 4.17 (m, 3'-H), 5.01 (t, 5'-OH), 6.22 (dd, 1'-H), 6.37 (br. s, 2-NH₂), 7.15 (s, 8-H), 10.47 (s, N¹H) ppm, $J_{1',2'} = 5.61$ Hz, $J_{10,11} = 6.03$ Hz; ¹³C-NMR (75 MHz, DMSO-d_6, 300 K): $\delta = 18.27 (11-C)$, 36.43 (2'-C), 55.21 (7-C), 61.82 (5'-C), 63.41 (10-C), 80.01 (3'-C), 82.17 (1'-C), 84.32 (4'-C), 99.90 (5-C), 119.26 (12-C), 121.61 (8-C), 150.67, 152.75 (2-C, 4-C), 158.01 (6-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 445.02 [C₁₄H₁₆IN₅O₄], found: 446.0 [M+H]⁺.

1.4 Synthesis and attachment of the linker

1.4.1 Synthesis of the alkyne modified linker Prop-2-inylcarbamic acid 1-{2-[2-(2-*tert*-butoxycarbonylaminoethoxy)ethoxy]ethoxy-methyl}-2-cyanoethyl ester 23



The solution of compound **22** (867 mg, 2.61 mmol, 1.0 eq.) in 50 mL of dry CH₃CN was cooled to 0 °C and 364 mg (2.61 mmol, 1.0 eq.) of water free K₂CO₃ were added. The suspension was stirred for 2 h at 0 °C before 1.41 g (5.22 mmol, 2.0 eq.) of DSC were added and stirring was continued for further 20 h at 0 °C. Afterwards 655 mg (6.52 mmol, 2.5 eq.) of KHCO₃ and 540 μ L (8.35 mmol, 3.2 eq.) of propargylamine were added and the mixture stirred at 0 °C for 1 h and at room temperature for 4 h. The solvent was removed in vacuum and the residue divided between 50 mL of saturated NaHCO₃-solution and 50 mL of CH₂Cl₂. The organic layer was washed with 50 mL of CH₂Cl₂. The combined organic layers were dried over Na₂SO₄ and the solvent was removed in vacuum after filtration. The oily residue was purified by flash-column chromatography (CH₂Cl₂/MeOH = 99:1 to CH₂Cl₂/MeOH = 98:2) affording 728 mg (68 %) of compound **23** as colourless oil.

TLC: **R**_{**F**} = 0.25 (CH₂Cl₂/MeOH = 95:5); ¹**H-NMR** (250 MHz, DMSO-d₆, 300 K): δ = 1.37 (s, 13-H₉), 2.77-2.95 (m, 2-H₂), 3.06 (q, 10-H₂), 3.10 (t, 17-H), 3.37 (t, 9-H₂), 3.47-3.62 (m, 4-H₂, 5-H₂, 6-H₂, 7-H₂, 8-H₂), 3.78 (dd, 15-H₂), 4.95 (,,quintett", 3-H), 6.74 (t, N^{Boc}*H*), 7.87 (t, N*H*) ppm, *J*_{9,10} = 5.9 Hz, *J*_{15,NH'} = 5.8 Hz, *J*_{15,17} = 2.5 Hz; ¹³**C-NMR** (62.5 MHz, DMSO-d₆, 300 K): δ = 19.71 (2-C), 28.22 (13-C), 29.82 (15-C), 39.68 (10-C), 67.86 (3-C), 69.17 (9-C), 69.50, 69.61, 69.74, 70.20, 70.31 (4-C, 5-C, 6-C, 7-C, 8-C), 73.14 (17-C), 77.60 (12-C), 81.06 (16-C), 117.67 (1-C), 154.87 (14-C), 155.57 (11-C) ppm; **ESI**(+)-**MS** *m/z*: calc.: 413.47 [C₁₉H₃₁N₃O₇], found: 436.1 [M+Na]⁺, 414.2 [M+H]⁺, 314.0 [M-Boc+H]⁺; **EA** (%): calc.: C: 55.19, H: 7.56, N: 10.16, found: C: 55.09, H: 7.59, N: 10.04.

1.4.2 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2tert-butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'desoxyadenosine 26



Following **GP 2** (see experimental section in the article) 150 mg (0.35 mmol, 1.0 eq.) of 7-deaza-7iodo-3'-O-(2-cyanoethyl)-2'-deoxyadenosine **16** and 217 mg (0.52 mmol, 1.5 eq.) of alkyne **23** gave, after flash-column chromatography (CH₂Cl₂/MeOH = 99:1 to CH₂Cl₂/MeOH = 95:5), 168 mg (67 %) of compound **26** as slightly yellow foam.

TLC: **R**_F = 0.38 (CH₂Cl₂/MeOH = 90:10); ¹**H-NMR** (400 MHz, DMSO-d₆, 300 K): δ = 1.36 (s, 26-H₉), 2.33-2.41 (m, 2'-H), 2.52-2.60 (m, 2'-H'), 2.80 (t, 28-H₂), 2.86 (dd, 15-H), 2.92 (dd, 15-H'), 3.05 (q, 23-H₂), 3.35 (t, 22-H₂), 3.44-3.62 (m, 5'-H₂, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂), 3.65-3.71 (m, 27-H₂), 3.96-3.99 (m, 4'-H), 4.07 (d, 12-H₂), 4.23-4.27 (m, 3'-H), 4.99 (quintett, 14-H), 5.17 (t, 5'-O*H*), 6.42 (dd, 1'-H), 6.69-6.75 (m, 23-N*H*), 6.00-7.45 (br. s, 6-N*H*₂), 7.73 (s, 8-H), 8.03 (t, 12-N*H*), 8.10 (s, 2-H) ppm, $J_{12,12-NH} = 5.2$ Hz, $J_{15,15'} = 17.1$ Hz; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): δ = 18.26 (28-C), 19.73 (15-C), 28.21 (26-C), 30.97 (12-C), 36.58 (2'-C), 39.67 (23-C), 61.83 (5'-C), 63.40 (27-C), 67.93 (14-C), 69.15 (22-C), 69.46, 69.59, 69.71, 70.20, 70.29 (17-C, 18-C, 19-C, 20-C, 21-C), 75.42 (10-C), 77.59 (25-C), 79.90 (3'-C), 83.19 (1'-C), 84.71 (4'-C), 88.81 (11-C), 94.70 (7-C), 102.28 (5-C), 117.68 (16-C), 119.21 (29-C), 125.97 (8-C), 149.28 (4-C), 152.71 (2-C), 155.14 (13-C), 155.56 (24-C), 157.51 (6-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 714.77 [C₃₃H₄₆N₈O₁₀], found: 715.8 [M+H]⁺; **EA** (%): calc.: C: 55.45, H: 6.49, N: 15.68, found: C: 55.41, H: 6.59, N: 15.42.

1.4.3 Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-*tert*butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxycytidine 25



Following **GP 2** (see experimental section in the article) the reaction of 77 mg (0.19 mmol, 1.0 eq.) 5-iodo-3'-O-(2-cyanoethyl)-2'-deoxycytidine **13** and 157 mg (0.38 mmol, 2.0 eq.) of alkyne **23** gave, after flash-column chromatography (CH₂Cl₂/MeOH = 98:2 to CH₂Cl₂/MeOH = 92:8), 102 mg (78 %) of compound **25** as yellowish foam.

TLC: **R**_F = 0.11 (CH₂Cl₂/MeOH = 90:10); ¹**H-NMR** (400 MHz, DMSO-d₆, 300 K): δ = 1.37 (s, 23-H₉), 2.03-2.12 (m, 2'-H), 2.25-2.32 (m, 2'-H'), 2.77 (t, 25-H₂), 2.84 (dd, 12-H), 2.91 (dd, 12-H'), 3.05 (q, 20-H₂), 3.36 (t, 19-H₂), 3.47-3.65 (m, 5'-H₂, 24-H₂, 14-H₂, 15-H₂, 16-H₂, 17-H₂, 18-H₂), 3.93-3.97 (m, 4'-H), 4.06 (d, 9-H₂), 4.10-4.15 (m, 3'-H), 4.93-4.99 (m, 11-H), 5.11-5.16 (m, 5'-OH), 6.08 (t, 1'-H), 6.70-6.76 (m, 20-N*H*), 6.82 (s, 4-N*H*), 7.80 (s, 4-N*H*'), 7.88-7.94 (m, 9-N*H*), 8.09 (s, 6-H) ppm, $J_{12,12'}$ = 17.3 Hz, $J_{19,20}$ = 5.9 Hz; ¹³C-NMR (100 MHz, DMSO-d₆, 300 K): δ = 18.22 (25-C), 19.73 (12-C), 28.22 (23-C), 31.08 (9-C), 37.58 (2'-C), 39.67 (20-C), 61.20 (5'-C), 63.53 (24-C), 67.93 (11-C), 69.16 (19-C), 69.48, 69.60, 69.73, 70.20, 70.30 (14-C, 15-C, 16-C, 17-C, 18-C), 74.59 (7-C), 77.58 (22-C), 79.17 (3'-C), 84.77 (4'-C), 85.31 (1'-C), 89.46 (5-C), 91.64 (8-C), 117.68 (13-C), 119.15 (26-C), 143.89 (6-C), 153.35 (2-C), 154.82 (10-C), 155.56 (21-C), 164.30 (4-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 691.73 [C₃₁H₄₅N₇O₁₁], found: 692.3 [M+H]⁺, 714.4 [M+Na]⁺; **EA** (%): calc.: C: 53.83, H: 6.56, N: 14.17, found: C: 53.57, H: 6.62, N: 13.98. 1.4.4 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2tert-butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyguanosine 27



Following **GP 2** (see experimental section in the article) the reaction of 187 mg (0.42 mmol, 1.0 eq.) of 7-deaza-7-iodo-3'-O-(2-cyanoethyl)-2'-deoxyguanosine **21** and 260 mg (0.63 mmol, 1.5 eq.) of alkyne **23** yielded, after flash-column chromatography (CH₂Cl₂ to CH₂Cl₂/MeOH = 90:10), 230 mg (75 %) of compound **27** as slightly yellow foam.

TLC: **R**_F = 0.36 (CH₂Cl₂/MeOH = 90:10); ¹**H-NMR** (300 MHz, DMSO-d₆, 300 K): δ = 1.37 (s, 26-H₉), 2.26 (ddd, 2'-H), 2.36-2.47 (m, 2'-H'), 2.79 (t, 28-H₂), 2.82-2.97 (m, 15-H₂), 3.05 (q, 23-H₂), 3.36 (t, 22-H₂), 3.46-3.62 (m, 5'-H₂, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂), 3.65 (t, 27-H₂), 3.87-3.94 (m, 4'-H), 4.02 (d, 12-H₂), 4.14-4.20 (m, 3'-H), 4.91-5.05 (m, 14-H, 5'-OH), 6.22 (dd, 1'-H), 6.35 (br. s, 2-NH₂), 6.73 (t, 23-NH), 7.27 (s, 8-H), 7.917 (t, 12-NH), 10.50 (s, N¹H) ppm, $J_{12,12-NH}$ = 5.5 Hz, $J_{27,28}$ = 6.1 Hz; ¹³C-NMR (75 MHz, DMSO-d₆, 300 K): δ = 18.23 (28-C), 19.70 (15-C), 28.18 (26-C), 30.62 (12-C), 36.50 (2'-C), 39.65 (23-C), 61.79 (5'-C), 63.40 (27-C), 67.78 (14-C), 69.13 (22-C), 69.45, 69.56, 69.69, 70.18, 70.28 (17-C, 18-C, 19-C, 20-C, 21-C), 76.24 (10-C), 77.55 (25-C), 79.99 (3'-C), 82.23 (1'-C), 84.37 (4'-C), 86.37 (11-C), 98.46 (7-C), 99.34 (5-C), 117.64 (16-C), 119.20 (29-C), 122.02 (8-C), 150.34 (4-C), 153.18, 157.72 (2-C, 6-C), 154.83 (13-C), 155.52 (24-C) ppm; **ESI**(+)-**MS** (*m*/*z*): calc.: 730.77 [C₃₃H₄₆N₈O₁₁], found: 731.6 [M+H]⁺, 753.6 [M+Na]⁺, 769.6 [M+K]⁺; **EA** (%): calc.: C: 54.24, H: 6.34, N: 15.33, found: C: 54.00, H: 6.31, N: 15.21.

1.5 Triphosphate synthesis and attachment of the dye

1.5.1 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2*tert*-butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxyadenosine 5'triphosphate 30



Following **GP 3** (see experimental section in the article) 161 mg (0.23 mmol, 1.0 eq.) of the *N*-Boc protected nucleoside **26** gave 36 mg (19 %) of triphosphate **30** as yellowish oil. The yield was calculated from the ¹H-NMR spectrum as the product contained rests of triethylammonium acetate after HPLC purification.

RP-TLC: **R**_F = 0.71 (H₂O/CH₃CN = 80:20); **IE-FPLC**: elution concentration: 0.34 M TEAB-buffer (45 % B); **RP-HPLC**: retention time: 16.65 min; ¹**H-NMR** (400 MHz, D₂O, 300 K): δ = 2.63 (m, 2'-H₂), 2.87 (t, 25-H₂), 2.92-3.04 (m, 15-H₂), 3.12-3.18 (m, 23-H₂), 3.49-3.81 (m, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂, 22-H₂), 3.90 (t, 24-H₂), 4.09-4.27 (m, 5'-H₂, 12-H₂), 4.41 (br. s, 4'-H), 4.55 (br. s, 3'-H), 5.20-5.29 (m, 14-H), 6.54 (t, 1'-H), 7.72 (s, 8-H), 8.18 (s, 2-H) ppm, *J*_{23,24} = 5.8 Hz; ¹³C-**NMR** (62.5 MHz, D₂O, 300 K): δ = 19.01 (25-C), 20.26 (15-C), 31.66 (9-C), 36.85/37.05 (2'-C), 39.44/39.49 (23-C), 64.46 (24-C), 66.52 (d, 5'-C), 66.90/66.94, 69.82, 69.89, 70.02, 70.72/70.78, 71.24 (17-C, 18-C, 19-C, 20-C, 21-C, 22-C), 69.12/69.23 (14-C), 75.43/75.48 (10-C), 80.77/80.88 (3'-C), 83.65 (m, 4'-C), 83.82 (1'-C), 89.71 (11-C), 96.63/96.71 (7-C), 103.31 (5-C), 118.76 (16-C), 120.55 (26-C), 126.52/126.70 (8-C), 149.09/149.19 (4-C), 152.78/152.85 (2-C), 157.42 (6-C), 157.59 (13-C) ppm, *J*_{5',α-P} = 5.81 Hz; ³¹P-NMR (121 MHz, D₂O, 300 K): δ = -10.62 (d, γ-P), -11.32 (d, α-P), -23.04 (t, β-P) ppm; **ESI(-)-MS** (*m*/z) calc.: 854.59 [C₂₈H₄₁N₈O₁₇P₃], found: 853.6 [M-H]⁻.

1.5.2 Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-*tert*butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxycytidine 5'-triphosphate 29



Following **GP 3** (see experimental section in the article) 236 mg (0.34 mmol, 1.0 eq.) of the *N*-Boc protected nucleoside **25** yielded 23 mg (8 %) of triphosphate **29** as colourless oil. The yield was calculated from the ¹H-NMR spectrum as the product contained rests of triethylammonium acetate after HPLC purification.

RP-TLC: **R**_F = 0.77 (H₂O/CH₃CN = 80:20); **IE-FPLC**: elution concentration: 0.31 M TEAB-buffer (35 % B); **RP-HPLC**: retention time: 15.10 min; ¹**H-NMR** (300 MHz, D₂O, 300 K): δ = 2.24-2.34 (m, 2'-H), 2.58-2.67 (m, 2'-H'), 2.86 (t, 22-H₂), 2.92-2.99 (m, 12-H₂), 3.24 (m, 20-H₂), 3.69-3.79 (m, 14-H₂, 15-H₂, 16-H₂, 17-H₂, 18-H₂, 19-H₂), 3.88 (t, 21-H₂), 4.18-4.30 (m, 5'-H₂, 9-H₂), 4.39-4.45 (m, 4'-H), 4.46-4.52 (m, 3'-H), 5.20-5-29 (m, 11-H), 6.26-6.34 (m, 1'-H), 8.22/8.23 (s, 6-H) ppm, *J*_{21,22} = 5.9 Hz; ¹³**C-NMR** (75 MHz, D₂O, 300 K): δ = 18.90 (22-C), 20.18/20.21 (12-C), 31.54 (9-C), 37.82/37.91 (2'-C), 39.65 (20-C), 64.44/64.45 (21-C), 66.28 (d, 5'-C), 66.93, 70.05, 70.13, 70.18, 70.80, 71.22 (14-C, 15-C, 16-C, 17-C, 18-C, 19-C), 69.31 (11-C), 73.47 (7-C), 80.42/80.51 (3'-C), 84.29 (m, 4'-C), 87.07/87.22 (1'-C), 92.78, 93.12 (5-C, 8-C), 118.79 (13-C), 120.44 (23-C), 145.57 (6-C), 156.09/156.13 (2-C), 157.39 (10-C), 165.31 (4-C) ppm, J_{5',α-P} = 6.49 Hz; ³¹**P-NMR** (121 MHz, D₂O, 300 K): δ = -10.85 (d, γ-P), -11.53 (d, α-P), -23.21 (t, β-P) ppm, *J*_{α,β} = 20.0 Hz; **ESI(-)-MS** (*m*/z): calc.: 831.55 [C₂₆H₄₀N₇O₁₈P₃], found: 830.5 [M-H]⁻.

1.5.3 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2tert-butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxyguanosine 5'triphosphate 31



Following **GP 3** (see experimental section in the article) 72 mg (0.1 mmol, 1.0 eq.) of the *N*-Boc protected nucleoside **27** gave 22 mg (26 %) of triphosphate **31** as colourless oil. The yield was calculated from the ¹H-NMR spectrum as the product contained rests of triethylammonium acetate after HPLC purification.

RP-TLC: **R**_F = 0.64 (H₂O/CH₃CN = 90:10); **IE-FPLC**: elution concentration: 0.35 M TEAB-buffer (40 % B); **RP-HPLC**: retention time: 15.13 min; ¹**H-NMR** (300 MHz, D₂O, 300 K): δ = 2.54 (ddd, 2'-H), 2.58-2.70 (m, 2'-H'), 2.85 (t, 25-H₂), 2.89-2.98 (m, 15-H₂), 3.17 (23-H₂, from 2D-NMR, hidden below Et₃N signal), 3.55-3.80 (m, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂, 22-H₂), 3.89 (dt, 24-H₂), 4.06-4.28 (m, 5'-H₂, 12-H₂), 4.36 (m, 4'-H), 4.53 (br. d, 3'-H), 5.21 (m, 14-H), 6.38 (dd, 1'-H), 7.40 (s, 8-H) ppm, $J_{1',2'}$ = 5.8 Hz; ¹³C-NMR (150 MHz, D₂O, 300 K): δ = 18.97 (25-C), 20.16 (15-C), 31.64 (12-C), 36.69 (2'-C), 39.56 (23-C), 64.36 (24-C), 66.50 (d, 5'-C), 66.92, 69.96, 70.10 (2C), 70.78, 71.25 (17-C, 18-C, 19-C, 20-C, 21-C, 22-C), 69.13 (14-C), 76.09 (10-C), 80.89 (3'-C), 83.63 (d, 4'-C), 83.92/83.98 (1'-C), 87.74, 99.22, 100.61 (5-C, 7-C, 11-C), 118.72 (16-C), 120.48 (26-C), 124.44/124.63 (8-C), 151.49 (4-C), 153.84, 161.23 (2-C, 6-C), 157.38/157.42 (13-C) ppm, $J_{4'-\alpha-P}$ = 9.22 Hz, $J_{5'-\alpha-P}$ = 5.63 Hz; ³¹P-NMR (121 MHz, D₂O, 300 K): δ = -10.70 (d, γ-P), -11.39 (d, α-P), -23.14 (t, β-P) ppm; **ESI(-)-MS** (*m/z*): calc.: 870.59 [C₂₆H₄₀N₇O₁₈P₃], found: 870.0 [M-H]⁻.

1.5.4 General procedure for the purification of labelled triphosphates (GP 4)

Two chromatographic purification steps were carried out on the concentrated, crude reaction mixtures of compounds 2, 3, 4, and 5. The first step was a purification by RP-FPLC at 4 °C as described in the materials and methods. The following gradient was used for all four compounds: **RP-FPLC**: flow rate: 3 mL/min, gradient: 0 mL: 0 % B \rightarrow 60 mL: 1 % B \rightarrow 120 mL: 5 % B \rightarrow 160 mL: 10 % B \rightarrow 220 mL: 20 % B \rightarrow 250 mL: 50 % B \rightarrow 280 mL: 100 % B \rightarrow 310 mL: 100 % B, The second step was a purification by RP-HPLC as described in the materials and methods. The following gradients were used.

For compounds **3** and **4**:

RP-HPLC (**A**, **C**): flow rate: 6 mL/min, gradient: 0 min.: 10 % A, 90 % B, 0 % C→15 min.: 10 % A, 60 % B, 30 % C→16 min.: 0 % A, 0 % B, 100 % C→22 min.: 0 % A, 0 % B, 100 % C→23 min.: 10 % A, 90 % B, 0 % C→30 min.: 10 % A, 90 % B, 0 % C For compounds **2** and **5**:

RP-HPLC (**T**, **G**): flow rate: 6 mL/min, gradient: 0 min.: 10 % A, 90 % B, 0 % C 18 min.: 10 % A, 54 % B, 36 % C→18.5 min.: 0 % A, 0 % B, 100 % C→26.5 min.: 0 % A, 0 % B, 100 % C→27 min.: 10 % A, 90 % B, 0 % C→30 min.: 10 % A, 90 % B, 0 % C.

1.5.5 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-5and 6-carboxy-X-rhodamineamidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyadenosine 5'-triphosphate 3



To a solution of 20 mg (23 μ mol, 1.0 eq.) of the triphosphate **30** in 500 μ L of dry DMF and 12 μ L (70 μ mol, 3 eq.) of *N*-ethyldiisopropylamine a solution of 5- and 6-carboxy-X-rhodamine-(*N*-hydroxyssuccinimidyl)ester (30 mg, 50 μ mol, 2.0 eq.) in 500 μ L of dry DMF was added in two portions. One half directly and the other half after 1 h at room temperature. The mixture was left stirring for 20 h at room temperature in the dark. After evaporation of the solvent the crude product

was dissolved in 3 mL of Millipore water and filtered through a 45 µm syringe filter before purification by RP-FPLC and preparative RP-HPLC (see **GP 4**). The triethylammonium salt of the labelled triphosphate **3** was obtained as dark red solid (5 mg, 16 %) as a mixture of the two regioisomers, each consisting of two diastereomers.

RP-TLC: **R**_F = 0.52 (H₂O/CH₃CN = 50:50); **RP-FPLC**: elution concentration: 13 % B – 100 % B; **RP-HPLC**: retention time: 18.87 min (UV detection), 19.06 min (fluorescence detection); **UV absorption**: 594 nm, 552 nm, 374 nm, 271 nm; **fluorescence**: excitation 592 nm, emission 610 nm; ¹**H-NMR** (400 MHz, D₂O, 300 K): δ = 1.55-2.13 (9H), 2.22-3.11 (20H), 3.33-4.32 (22H), 4.38-4.58 (1H) (each signal m, 2'-H₂, 3'-H, 4'-H, 5'-H₂, 12-H₂, 15-H₂, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂, 22-H₂, 23-H₂, 25-H₂, 26-H₂, 5- and 6-carboxy-X-rhodamine-H_{24,aliphatic}), 4.96-5.21 (m, 14-H), 5.92-8.81 (m, 1'-H, 2-H, 8-H, 5- and 6-carboxy-X-rhodamine-H_{5,aromatic}) ppm; ³¹**P-NMR** (121 MHz, D₂O, 300 K): δ = -10.73 (d, γ -P), -11.50 (d, α -P), -22.70 - -23.45 (m, β -P) ppm; **ESI(-)-MS** (*m/z*): calc.: 1371.18 [C₆₁H₆₉N₁₀O₂₁P₃], found: 684.7 [M-2H]²⁻, 1370.4 [M-H]⁻.

1.5.6 Synthesis of 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy 3.0amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2cyanoethyl)2'-deoxycytidine 5'-triphosphate 4



To a solution of 5 mg (6 μ mol, 1.0 eq.) of the triphosphate **29** in 250 μ L of dry DMF and 3 μ L (20 μ mol, 3 eq.) of *N*-ethyldiisopropylamine a solution of Cy 3.0-*N*-hydroxysuccinimidyl ester monopotassium salt (5 mg, 6 μ mol, 1.0 eq.) in 250 μ L of dry DMF was added. The mixture was left stirring for 20 h at room temperature in the dark. After evaporation of the solvent the crude product was dissolved in 3 mL of Millipore water and filtered through a 45 μ m syringe filter before purification by RP-FPLC and preparative RP-HPLC (see **GP 4**). The triethylammonium salt of the labelled triphosphate **4** was obtained as pink solid (3 mg, 36 %) as a mixture of two diastereomers.

RP-TLC: **R**_F = 0.66 (H₂O/CH₃CN = 80:20); **RP-FPLC**: elution concentration: 5 % B – 10 % B; **RP-HPLC**: retention time: 17.74 min (UV detection), 17.56 min (fluorescence detection); **UV absorption**: 550 nm, 519 nm, 292 nm; **fluorescence**: excitation 550 nm, emission 563 nm; ¹**H**-**NMR** (400 MHz, D₂O, 300 K): δ = 1.36 (aus 2D, 25/26/27/28-H₂, 52-H₃), 1.55-1.65 (m, 25/26/27/28-H₂), 1.701 (s, 37-H₆, 44-H₆), 1.812 (br. s, 25/26/27/28-H₂) 2.00-2.12 (m, 2'-H), 2.20 (m, 25/26/27/28-H₂), 2.37-2.47 (m, 2'-H'), 2.67 (t, 23-H₂), 2.87 (br. s, 12-H₂), 3.20-3.27 (m, 20-H₂), 3.39-3-68 (m, 14-H₂, 15-H₂, 16-H₂, 17-H₂, 18-H₂, 19-H₂), 3.70 (t, 22-H₂), 4.12 (m, 5'-H₂, 9-H₂, 29-H₂, 51-H₂), 4.22 (br. s, 4'-H), 4.34 (d, 3'-H), 5.12 (m, 11-H), 6.04 ("t", 1'-H), 6.33 (t, 39-H, 41-H), 7.36 (dd, 31/32/48/49-H₂), 7.79-7.85 (31/32/48/49-H₂), 7.87 (s, 32-H, 46-H), 8.05 (s, 6-H), 8.46 (t, 40-H) ppm, $J_{22,23}$ = 6.0 Hz, $J_{39,40}$ = 13.4 Hz, $J_{40,41}$ = 13.4 Hz; ³¹**P-NMR** (121 MHz, D₂O, 300 K): δ = -11.28 (br. s, α -P, γ -P), -23.61 (br. s, β -P) ppm; **ESI(-)-MS** (*m/z*): calc.: 1444.31 [C₅₇H₇₆N₉O₂₅P₃S₂], found: 480.4 [M-3H]³⁻, 721.0 [M-2H]²⁻, 681.0 [M-PO₃-2H]²⁻, 453.5 [M-PO₃-3H]²⁻, 732.1 [M+Na-2H]²⁻.

1.5.7 Synthesis of 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy 5.0-amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyguanosine 5'-triphosphate 5



To a solution of 5 mg (6 μ mol, 1.0 eq.) of the triphosphate **31** in 250 μ L of dry DMF and 4 μ L (23 μ mol, 4 eq.) of *N*-ethyldiisopropylamine a solution of Cy 5.0-*N*-hydroxysuccinimidyl ester monopotassium salt (5 mg, 6 μ mol, 1.0 eq.) in 250 μ L of dry DMF was added. The mixture was left stirring for 20 h at room temperature in the dark. After evaporation of the solvent the crude product was dissolved in 3 mL of Millipore water and filtered through a 0.45 μ m syringe filter before purification by RP-FPLC and preparative RP-HPLC (see **GP 4**). The triethylammonium salt of the labelled triphosphate **5** was obtained as dark blue solid (1.5 mg, 17 %) as a mixture of two diastereomers.

RP-TLC: **R**_F = 0.38 (H₂O/CH₃CN = 90:10); **RP-FPLC**: elution concentration: 5 % B – 10 % B; **RP-HPLC**: retention time: 18.55 min. (UV detection), 18.68 min (fluorescence detection); **UV absorption**: 648 nm, 605 nm, 319 nm, 245 nm; **fluorescence**: excitation 646 nm, emission 666 nm; ¹**H-NMR** (400 MHz, D₂O, 300 K): δ = 1.37 (from 2D, 28,29,30,31-H₂, 57-H₃), 1.61-1.69 (m, 28,29,30,31-H₂), 1.73, 1.74 (s, 40-H₆, 49-H₆), 1.78-1.86 (m, 28,29,30,31-H₂), 2.27 (t, 28,29,30,31-H₂), 2.44 (dd, 2'-H), 2.60-2.72 (m, 2'-H'), 2.78-2.90 (m, 15-H₂, 29-H₂), 3.32 (m, 23-H₂), 3.54-3.70 (m, 17-H₂, 18-H₂, 19-H₂, 20-H₂, 21-H₂, 22-H₂) 3.76-3.89 (m, 25-H₂), 3.93-4.28 (m, 5'-H₂, 12-H₂, 32-H₂, 56-H₂), 4.35 (br. s, 4'-H), 4.55 (d, 3'-H), 5.04 (m, 17-H), 6.18-6.45 (m, 1'-H, 42,43,44,45,46-H₂), 6.58 (t, 42,43,44,45,46-H₁), 7.30, 7.38 (d, 34-H, 54-H), 7.74-8.29 (8-H, 35-H, 37-H, 42,43,44,45,46-H₂, 51-H, 53-H) ppm; ³¹**P-NMR** (121 MHz, D₂O, 300 K): δ = -9.80 (br. s, γ-P), -11.32 (d, α-P), -22.56 (br. s, β-P) ppm; **ESI(-)-MS** (m/z): calc.: 1509.38 [C₆₁H₇₉N₁₀O₂₅P₃S₂], found: 508.1 [M+H₂O]³⁻, 722.9 [M-PO₄+Na]²⁻.

2 Spectra and chromatograms

2.1 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-aminoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)2'-desoxyuridine 5'-triphosphate 28







³¹P-NMR (D₂O):



ESI-MS spectrum:



S32

2.2 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-5- and 6carboxyfluoresceinamidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxyuridine 5'-triphosphate 2



Fluorescence spectrum (acquisition at 25 °C in deionised water):









ESI-MS spectrum:



2.3 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-*tert*butoxycarbonylaminoethoxy)ethoxy]ethoxy-methyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyadenosine 5'-triphosphate 30













2.4 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-5- and 6-carboxy-X-rhodamineamidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyadenosine 5'-triphosphate 3



Fluorescence spectrum (acquisition at 25 °C in deionised water):









ESI-MS spectrum:

2.5 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-*tert*butoxycarbonylaminoethoxy)ethoxy]-ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-deoxycytidine 5'-triphosphate 29



¹H-NMR (D₂O):







2.6 5-(Prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy 3.0amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)2'-deoxycytidine 5'-triphosphate 4



Fluorescence spectrum (acquisition at 25 °C in deionised water):







ESI-MS spectrum:



2.7 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-*tert*butoxycarbonylaminoethoxy)ethoxy]ethoxymethyl}-2cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyguanosine 5'-triphosphate 31





³¹P-NMR (D₂O):





2.8 7-Deaza-7-(prop-2-ynyl)carbamic acid-1-{2-[2-(2-Cy 5.0amidoethoxy)ethoxy]ethoxymethyl}-2-cyanoethyl ester-3'-*O*-(2-cyanoethyl)-2'-desoxyguanosine 5'-triphosphate 5



Fluorescence spectrum (acquisition at 25 °C in deionised water):









ESI-MS spectrum:

